<DOC>
	<DOCNO>NCT00001696</DOCNO>
	<brief_summary>Genistein natural product find soy bean ; consumption associate low incidence metastatic prostate cancer . Genistein known protein-tyrosine kinase inhibitor , preclinical study show increase cell adhesion . Increases cell adhesion vivo would phenotypically reverse first step metastatic cascade , potentially prevent metastasis formation , consistent epidemiologic finding . This study seek determine pharmacokinetics genistein human administer single dose genistein perform pharmacokinetic analysis . Patients treat two formulation genistein ( 43 % genistein preparation 90 % preparation ) . This phase I study , patient treat one three dosing level . Patients randomly assign receive one formulation first , follow washout period , receive second preparation ( i.e . randomize cross design ) . Information study use optimally design multiple dose study wherein patient treat long period time .</brief_summary>
	<brief_title>A Pharmacokinetic Study Genistein , Tyrosine Kinase Inhibitor</brief_title>
	<detailed_description>Genistein natural product find soy bean ; consumption associate low incidence metastatic prostate cancer . Genistein known protein-tyrosine kinase inhibitor , preclinical study show increase cell adhesion . Increases cell adhesion vivo would phenotypically reverse first step metastatic cascade , potentially prevent metastasis formation , consistent epidemiologic finding . This study seek determine pharmacokinetics genistein human administer single dose genistein perform pharmacokinetic analysis . Patients treat two formulation genistein ( 43 % genistein preparation 90 % preparation ) . This phase I study , patient treat one three dosing level . Patients randomly assign receive one formulation first , follow washout period , receive second preparation ( i.e. , randomize cross design ) . Information study use optimally design multiple dose study wherein patient treat long period time . The duration study estimate 4 week long patient .</detailed_description>
	<mesh_term>Genistein</mesh_term>
	<criteria>Must 18 year old great . ECOG performance status 01 . Individuals without history cancer eligible , history cancer . Individuals history cancer ( exclude nonmelanomatous skin cancer ) need submit pathology slide review Laboratory Pathology , NCI . Must able understand give informed consent . Life expectancy great 6 month . Hgb great equal 8.0gm/dl , platelet great equal 100,000/microliters , ANC great equal 1000/microliters , creatinine le equal 2.0/mg/dl , SGPT SGOT less equal 147 168 U/L , total bilirubin less equal 2 mg/dl ( patient high level bilirubin due familial defect bilirubin metabolism consider individual basis ) . No history breast cancer . No pregnant breast feeding subject . Must HIV positive . No history venous thrombosis within past year . No medical condition , , opinion investigator would jeopardize either patient integrity data obtain . No patient currently receive active therapy neoplastic disorder . However , patient prostate cancer LHRH agonist ( e.g. , Lupron Zoladex ) , undergone surgical castration , eligible study . No patient estrogen therapy . No patient take hormonal form contraception . No patient know soy intolerance .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>Anti-metastatic</keyword>
	<keyword>Chemoprevention</keyword>
	<keyword>Isoflavinoid</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Signal Transduction</keyword>
</DOC>